Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Centogene N.V. (CNTG : NSDQ)
 
 • Company Description   
Centogene is a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The Company?s goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using their knowledge of the global rare disease market, including epidemiological and clinical data and innovative biomarkers.

Number of Employees: 660

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.77 Daily Weekly Monthly
20 Day Moving Average: 37,918 shares
Shares Outstanding: (millions)
Market Capitalization: $ (millions)
Beta: -2.00
52 Week High: $14.00
52 Week Low: $5.77
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -40.64% -38.79%
12 Week -45.36% -45.90%
Year To Date -46.48% -51.66%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
AM STRANDE 7
-
ROSTOCK,2M 18055
DEU
ph: 38180113500
fax: -
investor.relations@centogene.com http://www.centogene.com
 
 • General Corporate Information   
Officers
Andrin Oswald - Chief Executive Officer
Flemming Ornskov - Chairman of the Supervisory Board
Richard Stoffelen - Chief Financial Officer
Hubert Birner - Member of the Supervisory Board
Jonathan G. Sheldon - Member of the Supervisory Board

Peer Information
Centogene N.V. (HLIS)
Centogene N.V. (APYI)
Centogene N.V. (RNVA)
Centogene N.V. (HMSY)
Centogene N.V. (LRSI)
Centogene N.V. (HAXS)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MEDICAL INFO SYS
Sector: Medical
CUSIP: N1976T109
SIC: 8071
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 04/21/22
Share - Related Items
Shares Outstanding:
Most Recent Split Date: (:1)
Beta: -2.00
Market Capitalization: $ (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.96 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.80 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 04/21/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.60
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -237.50%
vs. Previous Quarter: -140.00%
Sales Growth
vs. Year Ago Period: -16.10%
vs. Previous Quarter: -43.03%
ROE
09/30/21 - -56.32
06/30/21 - -25.39
03/31/21 - -29.84
ROA
09/30/21 - -24.54
06/30/21 - -11.57
03/31/21 - -13.19
Current Ratio
09/30/21 - 1.45
06/30/21 - 1.79
03/31/21 - 1.62
Quick Ratio
09/30/21 - 1.31
06/30/21 - 1.54
03/31/21 - 1.46
Operating Margin
09/30/21 - -14.29
06/30/21 - -6.88
03/31/21 - -9.23
Net Margin
09/30/21 - -14.29
06/30/21 - -6.88
03/31/21 - -9.23
Pre-Tax Margin
09/30/21 - -14.46
06/30/21 - -6.97
03/31/21 - -9.52
Book Value
09/30/21 - 2.22
06/30/21 - 3.46
03/31/21 - 3.83
Inventory Turnover
09/30/21 - 20.39
06/30/21 - 18.08
03/31/21 - 14.74
Debt-to-Equity
09/30/21 - 0.00
06/30/21 - 0.00
03/31/21 - 0.00
Debt-to-Capital
09/30/21 - 0.27
06/30/21 - 0.35
03/31/21 - 0.48
 

Powered by Zacks Investment Research ©